Senior Director, DMPK
$236k/y-$295k/y
3 days ago
Highlight
OnsiteFull-timeDirector
Summary
Revolution Medicines is seeking a Senior Director, DMPK to join their team in the San Francisco Bay Area. The role involves leading DMPK activities to support small molecule oncology pipelines and being a critical part of the Nonclinical Development and Clinical Pharmacology department.
About the Role
As a Senior Director, DMPK, you will develop and implement DMPK strategies for drug discovery and development programs, serve as a scientific leader in cross-functional discussions, design and manage nonclinical studies, and lead IND- and NDA-enabling activities. You will collaborate with various teams to establish optimized characteristics of lead candidates and contribute to developing combination strategies for late-stage development programs.
About You
Required:
- PhD in Pharmaceutic Sciences or a related scientific discipline with over 12 years of industry experience.
- Deep understanding of ADME principles and extensive knowledge in developing and implementing in vitro/in vivo assays and in silico tools.
- Strong track record in leading small molecule drug discovery programs and participating in IND submissions.
- Solid knowledge and experience in the application of PK and basic compartmental modeling software.
- Excellent time management, multi-tasking skills, and ability to work in cross-functional settings.
- Excellent verbal and written communication, problem-solving, and critical thinking skills.
Preferred:
- Experience in small molecule drug discovery and development in oncology.
- Prior experience in NDA and global marketing applications.
Benefits
- Competitive cash compensation.
- Robust equity awards.
- Strong benefits package including medical, dental, and vision coverage.
- Significant learning and development opportunities.
Revolution Medicines
We are Revolutionaries – passionate in our singular pursuit of discovering, developing and delivering innovative, targeted medicines for patients living with cancer. To deliver on our vision, we work relentlessly in pursuit of cutting-edge therapeutic approaches to some of the toughest cancers. Our current focus is on RAS-addicted cancers, which account for 30 percent of all new human cancer diagnoses.
San Francisco Bay Area